AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03848390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Time-restricted Feeding
Description: The modified time-restricted feeding arm will be asked to consume any food but will be asked to consume this food for only a 9 hour daytime period.
Study NCT03848390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: At least 30 minutes of physical activity per day 5 times per week.
Study NCT03848390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: At least 30 minutes of physical activity per day 5 times per week.
Study NCT03848390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Restricted consumption of sweetened beverages
Description: Restricted consumption of juice, soda, and other sweetened beverages.
Study NCT03848390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restricted consumption of sweetened beverages
Description: Restricted consumption of juice, soda, and other sweetened beverages.
Study NCT03750292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPAirX air filter
Description: It is a trademarked, patented (U.S. Patent # 7,802,443), U.S. FDA approved Class II medical re-circulating air cleaner, built by Air Innovations, Inc. (North Syracuse, NY) to provide improved indoor air quality in the bedrooms of asthmatic children. Units to be used in the proposed study have a 99.97% efficient filter for particles 0.3 µm in size. The device provides a clean air delivery rate (CADR) of 9 per hour with 1.8 of them being outdoor air.
Study NCT03750292 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: control air filter
Description: A placebo mode was added to the HEPAirX to provide only recirculation (without filtration or ventilation using outdoor air) and temperature control of the room air. The placebo filter is made of metal.
Study NCT01062711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey or soy protein
Description: Whey and casein are isolated milk proteins
Study NCT00920985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE (FC Patch Low, BAY86-5016)
Description: 21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 7 cycles and placebo tablets matching the conditions of the treatment of Arm 2
Study NCT00920985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A
Description: 21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1
Study NCT01774240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: systematic screening and treatment of delirium
Description: systematic screening for delirium with DOS scale and CAM ICU. In case of delirium, treatment according to guidelines.
Study NCT02597166 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ledipasvir/Sofosbuvir
Description: Each tablet of Harvoni contains 90 mg ledipasvir and 400 mg sofosbuvir.
Study NCT03605147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CaHMB
Description: Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by abdominal CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
Study NCT03859518 — intervention group
Intervention type: OTHER
Intervention: blood and skin samples
Description: To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.
Study NCT01431937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2018682
Description: Active Drug
Study NCT01431937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01615055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 20-40 mg fluoxetine po qd for 6 months
Study NCT01615055 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20-40 mg pharmacologically inactive tablets for 6 months
Study NCT04113174 — intervention group
Intervention type: OTHER
Intervention: Decision Analytic Modelling
Description: Prognostic models will be translated into a framework to guide clinical decision making by identifying relevant thresholds of predicted risk, above which implementation of our stated interventions is warranted.
Study NCT01062711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey or soy protein
Description: Whey and casein are isolated milk proteins
Study NCT00912613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICU Diary
Description: ICU Diary containing daily information of patients condition and treatment with appropriate photographs
Study NCT02896790 — intervention group
Intervention type: OTHER
Intervention: Interviews with 2 oncologists and 10 patients
Study NCT02896790 — intervention group
Intervention type: OTHER
Intervention: Interviews with 15 patients
Study NCT04140162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Induction: 16 mg/kg actual body weight IV weekly (weeks 1-8; total of 8 doses) then every 2 weeks (weeks 9-24; total of 8 doses).~Consolidation: 16 mg/kg actual body weight IV every four weeks (weeks 25-36)~Maintenance: 16 mg/kg actual body weight IV every eight weeks (weeks 37-88)~Sites will continue to use IV daratumumab to treat existing study patients until the IV daratumumab stock on site has been exhausted. The sites will then transition existing patient to SQ daratumumab. New patients will be started on SQ 1800mg daratumumab.~Induction- Cycles 1-2 (days 1, 8,15, 22), Cycles 3-6 (Weeks 9-24- two weeks (days 1, 15 ) Consolidation- Every 4 weeks on day 1 Maintenance- Every 8 weeks on day 1
Study NCT04140162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 1-24)~Consolidation: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 25-36)~Maintenance: 10 mg PO once daily, on days 1-21 of each 28-day cycle until progression or intolerance~Maintenance: 10 mg PO once daily, on days 1-21, weeks 37+ until progression
Study NCT04140162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Consolidation: 1.5 mg/m2 SQ on day 1, 8, 15 and 22 of each 28-day cycle (weeks 25-36)
Study NCT04140162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction and Consolidation: 40 mg (or reduced dose of 20 mg) PO or IV weekly
Study NCT04201626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adapted ERAS
Description: Each woman in the intervention group will attend a preoperative counseling session with nurse and doctors. In addition to the standard preoperative counseling, explaining the purpose, process, and the importance of ERAS protocol compliance will be added to the session. Preoperative nutrition and laboratory assessment will be done according to adapted ERAS protocol on that same visit.~During admission, the intervention group participants are provided with care according to adapted ERAS protocol including no bowel preparation, no extended fasting before surgery, balanced intravenous crystalloid, thromboprophylaxis, multimodal pain control reducing opioid usage, multimodal anti-emetics medications, stepping diet up to regular diet within 24 hours, chewing gum for post-operative ileus prevention, early removal of Foley's catheter, and promote early ambulation using care checklist plan.
Study NCT04643639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb hemoperfusion
Description: Subjects will be treated with CytoSorb hemoperfusion (in stand-alone setup) for 6 hours at a flow rate of 250 ml/min during endotoxemia.
Study NCT01752790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Top-down
Description: Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
Study NCT01752790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Step-up
Description: Patients randomized on Step-up arm will receive methylprednisolone (1 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day).Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
Study NCT00503334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: preOP booster (oral nutritional supplement, food for special medical purposes)
Description: 3x1 dosage pre-operatively
Study NCT00503334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: preOP booster (oral nutritional supplement, food for special medical purposes)
Description: 3x1 dosage pre-operatively
Study NCT03212417 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational intervention
Description: Presentation of risk factors, signs and symptoms, and interventions on compassion fatigue
Study NCT02976025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Longitudinal Remote Consultation
Description: Longitudinal Remote Consultation utilizes video conferencing to efficiently link providers to consultants who provide timely feedback and training in collaborative care. LRC will be provided in addition to standard collaborative care training and support.
Study NCT02976025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative Care
Description: Standard collaborative care implementation training and support.
Study NCT02253056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting / Caloric Restriction
Study NCT02253056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Diet
Study NCT02276118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: device: e.motion PS Pro
Description: patients will undergo total knee arthroplasty with e.motion PS Pro implant
Study NCT02276118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: device : Genesis II
Description: patients will undergo total knee arthroplasty with Genesis II implant
Study NCT03927313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: For both experimental arms: 1.2g linezolid 28 days, followed by 600mg linezolid for 28 days
Study NCT03927313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose rifampicin
Description: For both experimental arms: additional 25mg/kg (making a total of 35mg/kg) rifampicin, for the first 56 days of treatment
Study NCT03927313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: For only one of the experimental arms: 1000mg of aspirin daily for 56 days.
Study NCT03927313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care anti-tuberculous therapy
Description: 10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Levothyroxine sodium salt
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple compote Levothyroxine sodium salt
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Memantine
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple compote Memantine
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone
Study NCT01425411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: 80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months
Study NCT03874273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib 280mg/m2 twice a day (for 24 months maximum)
Study NCT03775044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medherent Device
Description: The Medherent Medication Management Device (MMD) is intended to enable patients to self-manage their medication at home when it may otherwise require assistance.
Study NCT01831258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensAwake On
Study NCT01831258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SensAwake Off
Study NCT03927313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care anti-tuberculous therapy
Description: 10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.
Study NCT03927313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone according to doses of Thwaites criteria for the first 8 weeks of anti-tuberculous treatment. Doses differ according to participants Medical Research Council (MRC) grade. Given orally if participant can swallow and intravenously if they cannot.
Study NCT03927313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone according to doses of Thwaites criteria for the first 8 weeks of anti-tuberculous treatment. Doses differ according to participants Medical Research Council (MRC) grade. Given orally if participant can swallow and intravenously if they cannot.
Study NCT03605147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
Study NCT04569136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The education session including education about mastitis, feeding techniques, lifestyle changes, thermal/cryo therapy and demonstration of breast self-massage will take approximately 20 minutes.
Study NCT04569136 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Education
Description: The education session including education about mastitis, feeding techniques, lifestyle changes, thermal/cryo therapy and demonstration of breast self-massage will take approximately 20 minutes.
Study NCT04569136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: Participants will be treated with 5 minutes of therapeutic ultrasound (pulsed mode) at a frequency of 1 Mega Hertz, a duty cycle of 20%, a pulse intensity of 1.8 Watt/centimetre squared. The ultrasound probe will be moved at a speed of about 4 centimetre/second. The intensity and duration will be adjusted if the patient complains of discomfort. The ultrasound transducer head will massage over the tender point on the breast.
Study NCT04569136 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham ultrasound
Description: Participants will receive 5 minutes of 'sham' ultrasound at 0 Watt/centimetre squared intensity from a physical therapist.
Study NCT04569136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast massage
Description: Breast massage includes general and focused massage. Participants will lie in supine position. The breast massage will be applied according to the Vodder method to the affected breast.
Study NCT04569136 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Breast massage
Description: Breast massage includes general and focused massage. Participants will lie in supine position. The breast massage will be applied according to the Vodder method to the affected breast.
Study NCT04569136 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual obstetric care
Description: Usual obstetric care may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff.
Study NCT03780478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: 0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL
Study NCT03780478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline Injection
Description: Saline injection, total volume 2ml
Study NCT00607711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral palifosfamide tris
Description: Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.
Study NCT01989689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50mg twice weekly
Study NCT01989689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept 50mg twice weekly
Study NCT01989689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02275390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Psycho-education (or SPBB: self-learning program)
Description: The program was modified from the psycho-educational, motivation-driven and emotionally supportive programs developed and previously tested by the research team in Chinese people with different kinds of serious mental illness, mainly including schizophrenia spectrum disorders and mood disorders by Chien and his colleagues in 2012, and adherence therapy for people with psychotic disorders by Gray et al. (2010).~\[Note: SPBB consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5: Dealing with \[physical and mental health\] effects of the illness).\]
Study NCT02275390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Psychiatric Outpatient Care
Description: These services consisted of medical consultation and treatment by the attending psychiatrist (i.e., around every four weeks), brief education sessions (i.e., 3 or 4 one-hour sessions) on mental illness and treatment received by psychiatric nurses, and advices and referrals for community mental health and social welfare services available and/or family counseling by a psychiatric nurse or medical social worker in each clinic.
Study NCT02275390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Psychiatric Outpatient Care
Description: These services consisted of medical consultation and treatment by the attending psychiatrist (i.e., around every four weeks), brief education sessions (i.e., 3 or 4 one-hour sessions) on mental illness and treatment received by psychiatric nurses, and advices and referrals for community mental health and social welfare services available and/or family counseling by a psychiatric nurse or medical social worker in each clinic.
Study NCT03362788 — intervention group
Intervention type: DRUG
Intervention: VKA
Description: VKA plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
Study NCT03362788 — intervention group
Intervention type: DRUG
Intervention: NOAC
Description: NOAC plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
Study NCT01989689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02873559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: Testosterone supplemented in 5 months
Study NCT02873559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle training
Description: Progressive muscle training during 4 months
Study NCT00391170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Dexamethasone
Description: dexamethasone 0.01%
Study NCT00391170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02878616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316
Description: LFG316 single dose
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple compote Zopiclone
Study NCT00492986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
Study NCT01884493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real iTBS
Description: Theta-burst magnetic stimulation (TBS) is a repetitive transcranial magnetic stimulation (rTMS) technique that elicits long-lasting changes in the excitability of human primary motor cortex (M1).
Study NCT02766283 — intervention group
Intervention type: DRUG
Intervention: iodinated contrast agents
Description: Intravascular application